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Available online 25 July 2016Laser therapy, recently renamed as photobiomodulation, stands as a promising supportive treatment for oralmu-
cositis induced by oncological therapies. However, its mechanisms of action and, more importantly, its safety in
cancer patients, are still unclear. Herewe explored the anti-cancer effect of 3 laser protocols, set at themost com-
monly used wavelengths, in B16F10 melanoma and oral carcinogenesis mouse models. While laser light in-
creased cell metabolism in cultured cells, the in vivo outcome was reduced tumor progression. This striking,
unexpected result, was paralleled by the recruitment of immune cells, in particular T lymphocytes and dendritic
cells, which secreted type I interferons. Laser light also reduced the number of highly angiogenic macrophages
within the tumor mass and promoted vessel normalization, an emerging strategy to control tumor progression.
Collectively, these results set photobiomodulation as a safety procedure in oncological patients and open theway
to its innovative use for cancer therapy.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The number of clinical and preclinical studies, assessing the use of
laser light in the prevention and treatment of oralmucositis (OM) in on-
cological patients undergoing chemo and/or radiotherapy, is rapidly
growing (Migliorati et al., 2013). Despite the exact mechanisms by
which laser light impacts on biological tissues have not been clariﬁed,
the remarkable reduction in local inﬂammation and promotion of
wound healing (Lins et al., 2010), eventually results in a rapid analgesic
effect and in a net improvement in the quality of life of the patients
(Chung et al., 2012).
Since 2009, we are successfully exploiting Class IV laser light in our
clinical practice for both the prevention and the treatment of radio/
chemo-induced OM and dermatitis (Chermetz et al., 2014, GOBBO et
al., 2014, Ottaviani et al., 2013, Gobbo et al., 2016), constantly obtaining
a faster wound healing and a reduced relapse frequency. We have re-
cently compared the efﬁcacy of low-power and high-power laserternational Centre for Genetic
149 Trieste, Italy.
. This is an open access article undertherapy (LPLT and HPLT) approaches, differing in their wavelength
(635 nm for the LPLT and 970 nm for the HPLT) and thus in tissue pen-
etration capacity. We found that both protocols, but mostly HPLT, are
able to stimulate the formation of new arterial vessels and the prolifer-
ation of vascular smooth muscle cells (Ottaviani et al., 2013).
These encouraging results also opened additional, relevant ques-
tions. In particular, considering that the laser therapy, recently named
as photobiomodulation (PBM) (Anders et al., 2015), is often applied to
head and neck oncological patients, what could be the consequence of
promoting angiogenesis and cell proliferation on either dysplastic or
neoplastic lesions within the oral cavity of the patients? A few studies
have so far assessed the effect of laser light on cancer cell metabolism
and proliferation, supporting the hypothesis that PBM could foster the
development and the growth of neoplastic lesions (De Castro et al.,
2005, Sperandio et al., 2013). However, studies investigating the effects
of laser irradiation on different tumor cell lines in vitro have generated
conﬂicting results, and very few of them considered the behavior of
tumor cells in vivo, using different protocols and obtaining inconsistent
data (Frigo et al., 2009).
Based on these considerations, here we explored the effect of PBM
both in cultured cells and in various in vivo models of cancer. Inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and L3), based on the wavelengths most commonly used in pre-clinical
and clinical studies (660, 800 and 970 nm, respectively).
2. Material and Methods
2.1. Laser Devices and Protocols
A gallium arsenide (GaAs) + indium gallium aluminium arsenide
phosphide (InGaAlAsP) diode laser device (class IV, K-Laser Cube series,
K-laser d.o.o., Sežana, Slovenia)was employed to irradiate cultured cells
and animals. To provide a uniform irradiation to multiwell plates, the
device was equipped with an adapted prototype probe, speciﬁcally de-
signed by Eltech S.r.l. Cells were seeded on sterile 24-well plates (well
area: 2 cm2) in 500 μl of medium without cover during irradiation.
The emission tip was hold perpendicular above the culture media and
the irradiation was carefully timed and carried out in a dark room. The
diode area laser source consisted of equal diodes, which emitted an el-
liptic laser ﬁeld with a Gaussian distribution of irradiance (Zacchigna
et al., 2014). The emitted light completely covered the irradiated ﬁeld
of each culture plate, as assessed using an optical powermeter. The con-
trol group was not exposed to laser, but during the laser treatment
dishes were removed from the incubator, the cover was removed and
cells were kept at room temperature (RT). Three different laser proto-
cols were employed:
- L1: λ 660 nm, laser power 100mW, irradiance 50 mW/cm2, ﬂuence
3 J/cm2, time 60 s, continuous wave
- L2: λ 800 nm, laser power 1W, irradiance 200mW/cm2, ﬂuence 6 J/
cm2, time 30 s, continuous wave
- L3: λ 970 nm, laser power 2.5 W, irradiance 200 mW/cm2, ﬂuence
6 J/cm2, time 30 s, continuous wave
The same protocols were applied in vivo, once a day for 4 consecu-
tive days, keeping the laser pointer perpendicular above the affected tis-
sues (tumor area 2 cm2).
2.2. Cell Lines and Primary Cells
Mouse B16F10 melanoma cells (CRL-6475; ATCC) and human bone
osteosarcoma cells (U2OS, HTB-96; ATCC)were grown in completeme-
diumwith DMEM1 g/L glucose supplementedwith 10% of FBS, 2 mM L-
glutamine, penicillin and streptomycin.
Human skin ﬁbroblasts (HSF, PCS-201-012; ATCC) were plated in
complete medium (PCS-201-041; ATCC). Commercial human umbilical
vein endothelial cells (HUVEC, CRL-1730; ATCC) were seeded onto gel-
atin pre-coated acrylic plates, in complete medium (EGM, CC-2517;
Lonza). Primary bone marrow-dendritic cells (BM-DCs) were isolated
by ﬂushing femura and tibiae of C57BL/6 male mice with RPMI-1640,
followed by red blood cell lysis with Ammonium-Chloride-Potassium
(ACK) buffer and supplementation with murine recombinant granulo-
cytemacrophage-colony stimulating factor (GM-CSF, 800 U/ml). Aggre-
gates of BM-DCs, evident upon removal of granulocytes and residual
lymphocytes, were dislodged by gentle pipetting, counted and plated.
mDCs were harvested after 7 days, when the number of CD11c+ was
higher than 80%. DCs were also treated with lipopolysaccharide (LPS,
200 ng/ml) endotoxin to promote the secretion of pro-inﬂammatory
cytokine.
2.3. In Vitro ATP Production Assay
Cells plated on 24-well plates were exposed to the various laser pro-
tocols and cell proliferation was measured at 24 and 48 h using the
ATPlite Luminescence Assay System (PerkinElmer, Waltham, MA),according to manufacturer's instructions. Experiments were performed
on 3 biological replicates, each one consisting of 3 technical replicates.
2.4. Animal Models
Animal care and treatmentwere conducted in conformitywith insti-
tutional guidelines in compliance with national and international laws
and policies (European Economic Community Council Directive 86/
609, OJL 358, December 12, 1987) and upon approval by the Institution-
al Animal Care Use Committee and by the Italian Minister of Health.
Ifnar1−/− (IFNAR KO) mice, lacking the α chain of the type IFN α/β re-
ceptor. on a C57BL/6 background were provided by U. Kalinke
(Twincore, Hannover Germany).
Animals (n= 48 C57BL/6 and n= 24, IFNAR KO 6-week-old female
mice) were housed under controlled environmental conditions for
5 days with a 12-hour light/dark cycle. Each animal was injected with
1 × 106 B16F10 melanoma cells at the dorsal subcutaneous level. After
10 days, when all masses were clearly detectable, C57BL/6 and IFNAR
KO mice were homogenously divided according to tumor size into 4
and 2 groups, respectively. C57BL/6 mice were treated with L1, L2 and
L3 protocols, while IFNAR KO mice with L3 protocol from day 11 to 14,
whereas one group was used as a control. Tumor volume and mice
weight were daily evaluated using a caliper and calculated applying
the following formula: V = π/6 * (dmax2 * dmin/2) (Tomayko and
Reynolds, 1989). At the end of the experiment (day 15) tumor masses
were eventually harvested for accurate measurement of their volume
and weight, prior to histological or ﬂow cytometry analysis.
For the oral carcinogenesis model, 50 6-week-old C57BL/6 female
mice were used, following the same guidelines described above. The
4-NQO carcinogen (Sigma-Aldrich) was dissolved in propylene glycol
(4 mg/ml), diluted in the drinking water to a ﬁnal concentration of
50 μg/ml, administered to mice for 16 weeks and replaced by regular
water starting from the 17th week. All mice were weighed every
4 weeks (Chang et al., 2010, Hawkins et al., 1994). Mice were random-
ized to receive only the 4-NQO carcinogen (n = 25, control) or to be
also exposed to the L3 laser protocol (n= 25, laser group) for 4 consec-
utive days during the 20th week. Dysplastic and neoplastic oral lesions,
mostly located on the ventral side of the tongue, were diagnosed and
processed to both macroscopic and microscopic examination by week
21.
Theminimal number of animals compatiblewith obtaining valid sci-
entiﬁc results was calculated by a statistical design of the sample size
using the software http://homepage.stat.uiowa.edu/~rlenth/Power/,
setting a variation coefﬁcient (s) of 30%, alpha of 5%, and a power of
80% (p).
Randomization was performed using a random number schedule
and the main experimenter was blind to group assignment.
2.5. Evaluation of Thermal Effect
The temperature of the medium inside the cell culture wells and on
the body surface of mice was monitored at baseline, during and after
PBM using the Ti20 Thermal Imager (Fluke), as graphically described
in Supplementary Fig. S1.
2.6. Histology and Immunoﬂuorescence
For histopathological evaluation, 5 μm tissue sections were stained
with haematoxylin and eosin and analyzed by three independent re-
viewers. The observed lesions were classiﬁed into 5 different types:
mild dysplasia (D1), moderate dysplasia (D2), severe dysplasia (D3),
in situ squamous cell carcinoma (SCC) or invasive SCC. Histopathologi-
cal diagnosis and grading were based on established criteria (Akhter
et al., 2011, Tang et al., 2004) to obtain the following measures: i) the
extension of each lesion (D1, D2, D3, in situ SCC, invasive SCC),
expressed as a percentage of the total perimeter of the tongue; ii) the
167G. Ottaviani et al. / EBioMedicine 11 (2016) 165–172number of areas involved by D1, D2, D3, in situ SCC, invasive SCC on
each tongue.
For immunohistochemistry tissue sections were stained with anti-
CD4, –CD8 (both from (Abgent), –DCIR2 (Novus Biologicals) and
Melan-A (Dako) primary antibodies (1:200), followed by Vectastain
ABC kit (Vector Laboratories), according to manufacturer's instructions.
For immunoﬂuorescence, tissue sections were stained with ﬂuorescein
isothiocyanate-labeled lectin (Lycopersicum esculentum; Vector Labo-
ratories), cyanine 3-labeled anti-αSMA antibodies (Sigma-Aldrich),
anti-BrdU (Abcam) or anti-CD31 (Pharmingen Becton Dickinson). All
primary antibodies were diluted 1:100, followed by AlexaFluor-conju-
gated secondary antibodies (Molecular Probes, 1:2000). Image acquisi-
tion was performed using either the ImageXpress Micro high-content
screening microscope (Molecular Devices) or confocal microscopy
(LSM510 META; Carl Zeiss) for subsequent three-dimensional (3D) re-
construction of the vascular network.
2.7. Real Time PCR
Total RNA was extracted using TRIzol (Invitrogen) and reverse tran-
scribed using hexameric random primers (Invitrogen). PCR ampliﬁca-
tion was performed using TaqMan Gene Expression Assays
(AppliedBiosystems). The RPL-37 housekeeping gene was used to nor-
malize the results. Experiments were performed on 3 biological repli-
cates, each one consisting of 3 technical replicates.
2.8. Flow Cytometry
For tumor inﬁltrate analysis, tumorswere harvested 10days after in-
oculation, digested with Collagenase type 2 (Worthington-Biochemical
Corporation), 265 U/ml for 30 min at 37 °C IV and then smashed
through a 70-μm nylon mesh ﬁlter (BD Falcon). Part of the mice was
subjected to in vivo perfusionwith PBS before tumor explantation to re-
move all blood cells, whereas tumors not subjected to perfusion were
treated with Ammonium-Chloride-Potassium (ACK) Lysing Buffer
(Gibco-ThermoFisher Scientiﬁc) for red blood cell lysis. For surface
staining, cells were incubated with anti-Fc receptor antibody (clone
93) and stained with antibodies in PBS + 1% bovine serum albumin
for 30 min on ice. Antibodies against CD45 (30-F11), CD11b (M1/70),
Ly6C (HK1.4), CD19 (1D3), CD4 (GK1.5) and CD8 (53-6.7) were pur-
chased from Biolegend, against CD11c (N418) and I-A/I-E (M5/
114.15.2) were purchased from eBioscience, against F4/80 (A13) were
purchased from Serotec. Analysis was performed using FACS Aria II
(BD Bioscience), according to the gating strategy shown in Supplemen-
tary Fig. S2. Dead cells weremarked by the LIVE/DEAD Fixable Cell Stain
(Invitrogen-ThermoFisher Scientiﬁc), which.
permeates the compromisedmembranes of necrotic cells and reacts
with free amines both inside the cells and on the cell surface, resulting in
intense ﬂuorescent staining. In contrast, in viable cells only the cell-sur-
face amines are available to react with the dye, resulting in relatively
dim staining. Dead cells, corresponding to the brightest population in
Supplementary Fig. S2, were excluded from the analysis.
2.9. Statistical analysis
Statistical signiﬁcance of the differences among the groups within
each time point for cell proliferation, and RT-PCR results was assessed
by two-way analysis of variance for repeated measurements using the
Kruskal–Wallis test.
In the case of experiments entailing the follow-up of the same ani-
mals over multiple time points, ANOVA on repeated measures (follow-
ed by Bonferroni post-hoc analysis) was used to analyze statistical
signiﬁcance of the differences between groups over time. All the differ-
ences concerningmice weight over timewithin each groupwere exam-
ined using the non-parametric Friedman test.All statistical assessments were two-sided, and P values b0.05 were
considered signiﬁcant. All analyses were performed using the SPSS 15.0
software.
3. Results
3.1. Laser Treatment Inhibits Tumor Growth and Invasion Without Directly
Affecting Tumor Cell Proliferation
To start exploring the possible effect of laser light on cell prolifera-
tion, we exposed various primary and cancer cell lines to three laser
protocols (L1, L2 and L3), set at increasing wavelengths. All protocols
slightly increased ATP content in primary skin ﬁbroblasts at 24 h and
this effectwasmaintained at 48 h especially for the L3 protocol (Supple-
mentary Fig. S3a). In the case of primary endothelial cells, the most ef-
fective protocols were L2 and L3 at both time points (Supplementary
Fig. S3b). Cell proliferation was transiently increased by laser treatment
also in U2OS osteosarcoma cells (L2 and L3 protocols) and B16F10mel-
anoma cells (L3 protocol), but no signiﬁcant differences in ATP content
or cell counts (not shown) were observed at 48 h after laser irradiation
for none of the tested cancer cells (Supplementary Fig. S3c, d). No signif-
icant changes in temperature were detected by a Thermal Imager for
any of the employed protocols (Supplementary Fig. S1a).
We then investigated the effect of the same protocols on tumor
growth in vivo, upon injection of B16F10 cells subcutaneously in synge-
neic C57BL/6 mice. All the animals developed a visible tumor mass of
comparable size 10 days after cell implantation, when they were ran-
domly divided into 4 experimental groups, each one assigned to a differ-
ent laser protocol (L1, L2, and L3) or left untreated (control). As shown
in Fig. 1a, the volume of the tumor mass progressively increased in all
groups, but starting from the last day of laser treatment (day 14), a
clear reduction in tumor growth rate was evident for all the three
laser protocols (P b 0.05 and P b 0.01 at day 14 and 15, respectively).
No signiﬁcant differences in either body weight or local body tempera-
turewere observed as a consequence of PBMwith all the employed pro-
tocols over time (Supplementary Figs. S3e and S1b).
Microscopic evaluation of tumor sections upon Melan-A staining,
which labels melanoma cells, revealed a remarkable inﬁltration of
tumor cells in the surrounding tissue in control animals (Fig. 1b upper
panels and 1c). A clear reduction in the number of inﬁltrating cells
was observed particularly upon tumor irradiation using the L3 protocol
(Fig. 1c and b, lower panels).
Thus, while laser light seems to increase the proliferation of cultured
cells, the net effect in vivo is a reduction of tumor growth and tumor cell
inﬁltration in surrounding tissues. This effect ismostly evident for the L3
protocol, which displays intermediate light penetration and the highest
power density.
3.2. Laser treatment improves perfusion and maturation of tumor vessels
Inspired by this unexpected ﬁnding, namely that laser light reduced
rather than increasing, tumor growth in vivo and by our previous data
supporting the angiogenic effect of PBM, we analyzed the tumor vascu-
lar network in treated and untreated animals. While we did not detect
any difference in the number of CD31+ endothelial cells, all the three
tested protocols markedly increased the number of α-SMA+ arteries
in both the tumoral and peri-tumoral areas (Fig. 1d, e). Considering
the importance of tumor-associated macrophages in controlling both
tumor growth and vascularization, we quantitatively assess macro-
phage inﬁltration by ﬂow cytometry. The analysis was performed either
on the whole tumor mass including the intravascular compartment, or
upon in vivo perfusion, thus excluding the intravascular compartment.
The total number of F4/80+ cells, which most likely tumor associated
macrophages, was not signiﬁcantly modiﬁed by laser treatment, either
in perfused or not perfused tumors, (Supplementary Fig. S4a) and im-
munohistochemistry (Supplementary Fig. S4b). Next, we better deﬁned
Fig. 1. Laser treatment reduces melanoma growth and invasionwhile promotingmaturation of tumor vessels. a. Assessment of tumor volume upon subcutaneous implantation of B16F10
melanoma cells in C57BL/6mice. b. Representative pictures of invasiveMelan-A+melanoma cells (black arrows) in the peritumoral area. Scale bar: 100 μm in the left panels and 200 μm in
the right panels. c. Number of Melan-A+ melanoma cells/ﬁeld in the peritumoral area. d. Number of α-SMA+ arteries/ﬁeld in the peritumoral area. e. Immunoﬂuorescence staining of
tumor vasculature showing CD31+ endothelial cells (green), α-SMA+ smooth muscle cells (red). Nuclei are stained with DAPI (blue). Scale bar: 100 μm. f, g. Flow cytometry analysis
of F4/80+Ly6C− (f) and F4/80+Ly6C+ pro-angiogenic macrophages (g), per gram of tumor, upon either in vivo perfusion or red blood cell lysis by Ammonium-Chloride-Potassium
(ACK). Data in a, c, d, f and g are expressed as means ± SD, *P b 0.05, **P b 0.01.
168 G. Ottaviani et al. / EBioMedicine 11 (2016) 165–172macrophage phenotype by sub-dividing them according to the relative
expression level of the Ly6C antigen.While F4/80+Ly6C−macrophages
were equally represented in perfused and not perfused tumors, and not
even changed upon laser treatment (Fig. 1f), clear differences were de-
tected in the abundance of F4/80+Ly6C+macrophages, typically associ-
ated to invasive, highly vascularized cancers (Movahedi et al., 2010).
Indeed, while these cells tended to be more represented within the in-
travascular compartment of laser-irradiated tumors, their extravascular
content was signiﬁcantly reduced by laser treatment (Fig. 1g). This ca-
pacity of laser light to reduce the number of resident F4/80+Ly6C+
macrophages, while increasing their intravascular content, is fully com-
patible with en effect of laser on improving the function of tumor ves-
sels, thereby resulting in increased tumor perfusion. Thus, L3 laser
treatment is effective in promoting structural and functionalmaturation
of tumor vessels in the melanoma syngeneic model.
We than validated the effect of laser light on tumor angiogenesis and
growth in a model of oral carcinogenesis, which better reproduces the
clinical condition. The administration of 4-NQO in the drinking water
for 16 weeks resulted in the appearance of either dysplastic or neoplas-
tic lesions in 100% of the animal tongues by week 20, when animals
were randomly divided into 2 groups, to be either exposed to the L3
protocol (the most effective protocol in the previous experiments) or
left untreated as controls. We ﬁrst stained tongue sections using anti-CD31 and anti-α-SMA antibodies. While CD31+ capillaries appeared
to have a more regular pattern but were not increased in number (not
shown), α-SMA+ arterioles were again signiﬁcantly increased in laser-
treated lesions (Fig. 2a, b).We also perfused the animals with ﬂuoresce-
in-labeled lectin to stain the intraluminal side of blood vessels. Whereas
control lesions showed an irregular pattern of vessels and extravascular
diffusion of the dye, indicating abnormal vascular permeability, laser
treatment resulted in a more regular and structured vessel pattern, in
the absence of dye leakage (Fig. 2c and Supplementary Movies 1,2).
What are the consequences of these vascular changes on cancerogenesis
progression? L3 laser treatment reduced the appearance of all kind of
dysplastic lesions (D1, D2 and D3; D1 + D2 + D3: 73 in the control
and 58 in the L3 groups, respectively; P b 0.05) and was even more ef-
fective in reducing the number and the percentage of both in situ and
invasive carcinomas (total SCC number: 38 in the control and 16 in
the L3 groups, respectively; P b 0.01; Supplementary Table 1). Of inter-
est, while in the control group, the carcinoma lesions were almost in-
variably surrounded by waves of dysplastic tissue (essentially D3 and
D2 lesions), similar to what normally happens in patients affected by
oral SCC, in a few instances the laser treatment resulted in a neoplastic
area completely surrounded by healthy tissue, as shown in Fig. 2d.
Thus, laser treatment inhibits tumor progression and improves func-
tional vessel maturation also in a model of oral carcinogenesis.
Fig. 2. Laser treatment inhibits tumor growth in a mouse model of oral carcinogenesis. a. Number of α-SMA+ arteries/ﬁeld in the peritumoral area. Data are expressed as means ± SD;
**P b 0.01 versus control. b. Immunoﬂuorescence staining of tumor vasculature showing CD31+ endothelial cells (green), α-SMA+ smooth muscle cells (red). Nuclei are stained with
DAPI (blue). Scale bar: 50 μm. c. Images of tongue sections from animals perfused in vivo with ﬂuorescein-labeled lectin (green) to stain the intraluminal side of vessels. Nuclei are
stained with DAPI (blue). Scale bars: 1 mm (upper panels) and 100 μm (lower panels). d. Haematoxylin-eosin staining of dysplastic and neoplastic lesions arose on mouse tongues
upon exposure to 4-NQO. A dividing line can be drawn to separate invasive carcinoma from healthy mucosa in a representative L3-treated animal (upper panel), whereas a wave of
progressive dysplasia was always present close to any carcinoma in control group (lower panel). SCC: squamous cell carcinoma. D2: moderate dysplasia. D3: severe dysplasia. Red
lines and numbers in the black square box indicate the size of each lesion. Scale bar: 100 μm.
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masses
Based on the evidence that laser light does not directly reduce tumor
cell proliferation but rather affected tumor vascularization, partially
modulating the inﬁltration of pro-angiogenic macrophages, we extend-
ed the analysis to other immune cell subsets, potentially able to inﬂu-
ence tumor microenvironment. We ﬁrst evaluated the global presence
of immune cells using the pan-leukocytic marker CD45. Remarkably,
the number of immune cells upon laser irradiation was signiﬁcantly in-
creased, an increment that was completely lost upon perfusion, indicat-
ing that leukocytes mostly resided within the intravascular
compartment (Supplementary Fig. S4c) and supporting the effect of
laser light in boosting tumor perfusion. We then moved assessing the
presence of tumor-inﬁltrating T lymphocytes (both CD4+ and CD8+
cells), which represent a longstanding topic of interest for their prog-
nostic signiﬁcance in the outcome of various cancers. By immunohisto-
chemical analysis of the border region between tumor and the
surrounding, healthy tissue, we could detect a higher density of these
cells (both CD4+ and CD8+ cells), which tended to get closer and
unwrap the tumor mass, particularly in the case of the L3 protocol
compared to untreated tumors (Fig. 3a and Supplementary Fig. S4d).However, when quantitatively assessing cell inﬁltration by ﬂow cytom-
etry, we foundno signiﬁcant differences in the content of any T lympho-
cyte type either in perfused or in not perfused animals (Fig. 3b, c).
Similar results were obtained for CD19+ B lymphocytes (Fig. 3d) and
CD11b+Ly6CintF4/80−SSChigh polymorphonuclear neutrophils (PMNs)
(Supplementary Fig. S4e), which were equally represented in treated
and untreated tumors, regardless of perfusion. Thus, laser light does
not have an impact on the number of inﬁltrating T lymphocytes, but
rather causes a re-distribution of these cells around the tumor mass.
Next, we focused our attention on dendritic cells (DCs), which also
potently inﬂuence tumor growth and invasion. Similar to what we
have observed for T lymphocytes, while in control tumors a few
DCIR2+DCswere detected around the neoplastic ﬁeld, upon laser treat-
ment, and especially upon L2 and L3 protocols, these cells get closer to
the tumor cells and often invaded the tumor mass itself (Fig. 3e). The
number of inﬁltrating CD11c+MHC-IIhighF4/80− DCs was not signiﬁ-
cantly affected by laser treatment neither in perfused nor in not per-
fused tumors. However, we observed a trend toward increased DC
density in L3-treated tumors in not perfused animals (Fig. 3f), suggest-
ing that incoming DCs gather closer to the tumor mass upon treatment.
To better investigate a potential, direct activity of PBM on DCs, we
prepared primary DC cultures from the mouse bone marrow. We were
Fig. 3. Laser treatment recruits immune cells around tumor masses. A. Immunohistochemistry of CD4+ and CD8+ lymphocytes inside the B16F10 tumormass, marked by an asterisk, and
in the peri-tumoral area, in control and L3 treated group. Scale bar: 50 μm. b–d and f. Flow cytometry analysis of the number of CD4+ T lymphocytes (b), CD8+ T lymphocytes (c), CD19+ B
lymphocytes (d) and CD11c+MHC-IIhighF4/80− DCs (f) in tumors subjected either to in vivo perfusion or to red blood cell lysis by Ammonium-Chloride-Potassium (ACK). Data are
expressed as means ± SD per gram of tumor (no signiﬁcant differences). e. Immunohistochemistry of DCIR2+ DCs (black arrows) inside the B16F10 tumor mass (black asterisk) in
control and laser-treated groups. Scale bar: 100 μm.
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posure of DCs to laser light, either in the presence or in the absence of
LPS, a potent inducer of DC activation (Supplementary Fig. S3f). Of inter-
est, whenwe assessed the capacity of DCs to secrete type I IFNs by ELISA,
we observed that the 3 laser protocols remarkably increased the pro-
duction of these cytokines, and in particular of IFNα, well known for
their potent anti-cancer activity (Lim et al., 2014; Picaud et al., 2002)
(Fig. 4a). We ﬁnally evaluated whether the expression levels of type I
IFNs were also changed within melanoma tumors in vivo upon laserFig. 4. Effect of laser treatment on DC activation and type I IFNs secretion. a. Real-time quantiﬁc
Real-time quantiﬁcation of IFNα, IFNβ and IFNγ mRNAs from B16F10 melanoma tumors fo
implantation of B16F10 melanoma cells in IFNAR KO mice. d. Immunohistochemistry of CD4
the peri-tumoral area in control and L3-treated IFNAR KO mice. Scale bar: 50 μm. e. Number
expressed as means ± SD. f. Immunohistochemistry of DCIR2+ DCs (black arrows) inside the
100 μm.treatment and found that the three protocols effectively up-regulated
the expression of these cytokines, consistent with their anti-tumor ef-
fect (Fig. 4b). Based on these results, we evaluated the effect of L3
laser irradiation on B16F10 tumor growth in IFNα receptor (IFNAR)
knockout (KO) mice, characterized by the complete absence of IFNα/β
activity (Muller et al., 1994). Tumor development was enhanced in
the IFNAR KO animals but not affected by laser treatment at any time
point (Fig. 4c). Different fromwild type animals, at microscopic evalua-
tion we could not detect any particular recruitment of T lymphocytes,ation of IFNα, IFNβ and IFNγ secreted by primary DCs following laser irradiation (24 h). b.
llowing laser irradiation (day 15). c. Assessment of tumor volume upon subcutaneous
+ and CD8+ lymphocytes inside the B16F10 tumor mass (marked by an asterisk) and in
of DCIR2+ cells/ﬁeld in the peritumoral area of wild type and IFNAR KO mice. Data are
B16F10 tumor mass (black asterisk) in control and L3-treated IFNAR KO mice. Scale bar:
171G. Ottaviani et al. / EBioMedicine 11 (2016) 165–172either CD4+ or CD8+ cells, around the tumormass upon laser treatment
(Fig. 4d). The number of DCs surrounding the tumor mass was overall
reduced in IFNAR KO animals, but again not affected by laser light (Fig.
4e, f). Thus, laser treatment loses its potential to inhibit tumor growth
and to foster immune cell recruitment toward the tumor mass in
IFNARKOmice, indicating a relevant role of IFNα and IFNβ inmediating
the effects of laser light in vivo.
4. Discussion
While we have designed this study to assess the safety of PBM, our
results provided novel, unexpected results. Not only tumor growth
was not increased by laser light, but also the 3 tested protocols effective-
ly reduced lesion size and markedly affected tumor microenvironment
in both B16F10 and oral carcinogenesis models. Our study presents
the following novelty features: i) it demonstrates that the effect of
laser light on cancer cell growth is different in cell culture and in vivo;
ii) it shows a remarkable effect of PBM on tumor vasculature, resulting
in a more structured and functional vascular network; iii) it unveils a
potent activity of laser light on immune modulation and DC activation,
mediated by type 1 IFNs.
The need to clearly establish the effect of laser light on cancer stems
from our routinely use of this technique for the treatment of radio/
chemo-therapy side effects (Chermetz et al., 2014, Gobbo et al., 2014,
Ottaviani et al., 2013). Despite a common consensus by the scientiﬁc
community on the efﬁcacy of PBM on mucosal injuries (Migliorati et
al., 2013), very few studies reliably assessed the effects of exposing dys-
plastic or even cancer tissues to laser irradiation, which represents a re-
alistic scenario in most oncological patients, as residual tumor cells may
still be present following oncological treatments for head and neck can-
cer, even in the absence of macroscopic lesions (Schartinger et al.,
2012).
Whilemost of the previous studiesmainly assessed the effect of laser
light on cancer cells in culture, here we intentionally explored whether
PBM exerted the same activity ex vivo and in vivo. We exposed various
primary cells and cancer cell lines to different laser protocols (L1, L2 and
L3) and noticed that in most instances, the net effect was a signiﬁcant
increase in cell metabolism and proliferation, in agreement with avail-
able literature data (Frigo et al., 2009). Of notice, not all cell types
responded in the same manner to each protocol, possibly indicating a
different content of endogenous porphyrins and cytochromes, which
are generally acclaimed as the primary laser light receptors (Farivar et
al., 2014). Indeed, primary cells tended to respond better to PBM than
cancer cells, which often carry abnormalities in their mitochondria.
Most relevant, when irradiating the same B16F10 cells ex vivo and in
vivo, we observed an opposite effect. Despite a modest, but signiﬁcant
increase in ATP content was detected in cultured cells upon exposure
to the L3, all 3 protocols markedly reduced tumor growth in vivo, as
well as the number of neoplastic cells inﬁltrating and invading of sur-
rounding tissues. These results are consistent with a few published re-
ports assessing the in vivo behavior of tumors exposed to laser light,
and showing that low power and energy doses have no inﬂuence on
tumor growth, or rather they can inhibit it (Abe et al., 1993).
The lower index of tumor growth and invasiveness in laser treated
animals, and especially in the L3 group, was accompanied by a notable
presence of immune cells (essentially T lymphocytes and DCs) around
the tumor mass. These ﬁndings are in line with the recent observation
that laser light can be exploited to activate dermal DCs to effectivelymi-
grate to draining lymph nodes and to induce antigen-speciﬁc CD8+ and
CD4+ T cell responses in the samemelanomamousemodel (Terhorst et
al., 2015). Besides opening theway to completely novel strategies to en-
hance cancer immunotherapy and vaccination in general, these data
also shed some light on the mechanisms by which PBM could inhibit
tumor growth in vivo, and thus be considered a safe procedure in cancer
patients. Notably, we showed that the direct irradiation of primary DCs
signiﬁcantly increased the secretion of type I IFNs and a consistent up-regulation of these cytokines was detected in vivo in B16F10 tumors
upon exposure to any of the 3 tested laser protocols. Type I IFNs are
well known for their peculiar anti-proliferative, pro-apoptotic and
anti-angiogenic properties, which are essential for immunosurveillance
of cancer, and already exploited clinically in a variety of malignancies
(reviewed in Zitvogel et al., 2015). The observation that laser treatment
completely lost its effect in IFNAR KOmice is a clear indication that IFNα
and IFNβ are essential mediators of the anti-cancer activity of laser light
in vivo. Atwhat extent the activation of immune cells, and in particular-
ly DCs, might also be responsible of the clearance od dysplastic lesions
observed in the oral carcinogenesis model, similarly to what observed
in human oral SCC (Upadhyay et al., 2012), still remains an open ques-
tion. Since it is known that mild hyperthermia can exert immune-mod-
ulatory activities (Knippertz et al., 2011), we cannot formally exclude
that the observed effects derive, at least in part, from cell and tissue
heating. However, the evidence that the most effective protocol (L3)
did not increase the temperature of either cultured cells or body surface,
points toward aminimal, if not null contribution of hyperthermia to the
anti-cancer effect of PBM.
From our analysis of intra-tumoral immune cell content by ﬂow cy-
tometry, we invariably detected an increased number of cells in not per-
fused compared to perfused animals in the L3 group. This is an indirect,
albeit strong indication that laser treatment enhanced the perfusion of
the tumor mass, thus increasing the number of cells within its intravas-
cular compartment. Of notice, whereas most of the immune cell types
were equally abundant within the extravascular space in control and
laser-treated animals, L3 therapy resulted in a signiﬁcant reduction on
the number of F4/80+Ly6C+ cells, which most probably represent
pro-angiogenic macrophages. This observation led us to analyze the
tumor vasculature in both the B16F10 and the oral carcinogenesis
models. In both cases, we observed that laser irradiation resulted in a
signiﬁcant increase in the number of α-SMA+ arterial vessels and a
more regular and structured vessel pattern, as assessed by immunoﬂu-
orescence and in vivo perfusion with ﬂuorescent lectin. The ultimate
outcome of these effects was the reduction of tumor progression, ﬁtting
the concept of “vessel normalization”, originally put forward as a goal to
improve blood supply and enhance drug delivery by low-dose anti-an-
giogenic agents and more recently emerging as an innovative strategy
to inhibit tumor growth rate (Carrer et al., 2012).
Collectively, our results clearly indicate that any experiment
assessing the effect of laser light on cultured cells is not representative
of the in vivo condition. Indeed, whereas laser light increased cell me-
tabolism and proliferation in cell culture, the overall effect in vivo was
a reduced tumor progression. These results were totally unexpected
and are deﬁnitely exciting in terms of clinical translatability, as they
set PBM as a safe procedure andwarrant further investigation exploring
its inclusion inmultimodal anti-cancer protocols in humans.Whichpro-
tocols should be put forward as the most effective ones? Our data tend
to indicate that L1 and L3, set at 660 nm and 970 nm respectively, could
be more efﬁcacious than L2 (800 nm) in activating immune cells and
normalizing tumor vessels, possibly because of their lower penetration
and enhanced activity on the more superﬁcial dermal and sub-mucosal
layers, where most of the immune cells and blood vessels normally
reside.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.07.028.
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